Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 17/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.63 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328859 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Neridronic Acid SCHEMBL87499 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL6668742 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL6665992 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL3287859 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL12821674 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL6667604 | 1.00 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D | |
| Neridronic Acid SCHEMBL328773 | 0.98 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| Neridronic Acid SCHEMBL10776647 | 0.98 | FDPS (0.96) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL3411395 | 0.98 | FDPS (1.00) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3346969-B1 | RADICALLY POLYMERIZABLE DENTAL MATERIAL | MUEHLBAUER TECH GMBH (DE) | 2021-07-14 | — | — | EP | disclosed |
| EP-2438076-B1 | TARGETED DRUG DELIVERY TO THE BONE | UNIV NANYANG TECH (SG) | 2018-12-19 | — | — | EP | disclosed |
| EP-3346969-A1 | RADICALLY POLYMERIZABLE DENTAL MATERIAL | Mühlbauer Technology GmbH (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-8933058-B2 | Targetted drug delivery to the bone | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2015-01-13 | — | — | US | disclosed |
| US-20140263071-A1 | METHOD FOR COLLECTING METALS | CHEMEC OY AB (FI) | 2014-09-18 | — | — | US | disclosed |
| US-8404144-B2 | Compositions including polymerizable bisphosphonic acids and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-8293029-B2 | Colored conversion layers on metal surfaces | HENKEL AG & CO. KGAA (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20120142641-A1 | TARGETTED DRUG DELIVERY TO THE BONE | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-06-07 | — | — | US | disclosed |
| EP-2438076-A1 | TARGETTED DRUG DELIVERY TO THE BONE | Nanyang Technological University (SG) | 2012-04-11 | — | — | EP | disclosed |
| EP-2407142-A1 | Use of polymerizable bisphosphonic acids for the treatment of tooth surfaces that are not pretreated with phosphoric acid | 3M Innovative Properties Company (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20090214883-A1 | CHROMIUM-FREE, THERMALLY CURABLE CORROSION PROTECTION COMPOSITION | HENKEL AG & CO. KGAA (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090075239-A1 | COMPOSITIONS INCLUDING POLYMERIZABLE BISPHOSPHONIC ACIDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2009-03-19 | — | — | US | disclosed |
| US-20060173099-A1 | Colored conversion layers on metal surfaces | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-08-03 | — | — | US | disclosed |
| EP-1578377-A1 | COMPOSITIONS INCLUDING POLYMERIZABLE BISPHOSPHONIC ACIDS AND METHODS | 3M Innovative Properties Company (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040206932-A1 | Compositions including polymerizable bisphosphonic acids and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-21 | — | — | US | disclosed |
| WO-2004060327-A1 | COMPOSITIONS INCLUDING POLYMERIZABLE BISPHOSPHONIC ACIDS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-0452345-A1 | PROCESS FOR IMPREGNATING ANODIZED ALUMINIUM SURFACES | Henkel Kommanditgesellschaft auf Aktien (DE) | 1991-10-23 | — | — | EP | disclosed |
| WO-1990007589-A1 | PROCESS FOR IMPREGNATING ANODIZED ALUMINIUM SURFACES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-07-12 | — | — | WO | disclosed |
| EP-0141200-B1 | DIHYDROXYALKANEDIPHOSPHONIC ACIDS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1988-07-27 | — | — | EP | disclosed |
| US-4536348-A | OUTSTANDING COMPLEXING POWER | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1985-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142641-A1 | TARGETTED DRUG DELIVERY TO THE BONE | SOST, BMP6, BMP2 | FDPS 346/4885PDE3A 1721/4885LMNA 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.